doi:10.3969/j.issn.1673-8640.2019.09.002

Abstract

CLC Number:

R446.1

Figures/Tables 4

References 7

[1]	罗将来,胡丽娜. 凝血功能检测在妊娠期糖尿病孕妇中的意义[J]. 重庆医学,2016,45(9):1210-1212.
[2]	汪成丽,张志坚,彭涛,等. 同型半胱氨酸水平对晚期孕妇血栓前状态标志物的影响[J]. 海南医学,2017,28(10):1602-1604.
[3]	KEBAPCILAR L,KEBAPCILAR A G,ILHAN T T,et al. Is the mean platelet volume a predictive marker of a low apgar score and insulin resistance in gestational diabetes mellitus? A retrospective case-control study[J]. J Clin Diagn Res,2016,10(10):OC06-OC10.
[4]	祖力卡提阿衣·阿布都拉,沙吉旦·阿布都热衣木,托兰古丽·买买提库尔班,等. 2型糖尿病合并冠心病患者血栓前状态与ALDH2基因多态性的相关性[J]. 职业与健康,2016,32(6):815-818.
[5]	DALY N,TURNER M J.Changing the diagnostic criteria for gestational diabetes mellitus? Gestational diabetes screening:the international association of the diabetes and pregnancy study groups compared with carpenter-coustan screening[J]. Obstet Gynecol,2016,127(4):800.
[6]	托兰古丽·买买提库尔班,帕丽达·阿布来提,祖力卡提阿衣·阿布都拉,等. 2型糖尿病合并冠心病及高血压患者血栓前状态和CYP2C19、ALDH2基因多态性的相关性研究[J]. 职业与健康,2016,32(10):1379-1383.
[7]	董媛媛,周越,王丹妹,等. 妊娠期糖尿病合并巨细胞病毒感染与凝血功能的相关性[J]. 中国热带医学,2016,16(9):914-916.

组别	PAGT：MAR（%）		TXB2（pg/mL）
组别	孕中期	孕晚期	孕中期	孕晚期
实验组	78.54±4.52	79.58±4.55	134.56±34.84	135.64±35.57
对照组	60.45±5.12	62.49±6.28	67.15±4.28	68.49±5.27
t值	21.518	12.070	15.601	10.228
P值	0.001	0.001	0.001	0.001

组别	PAGT：MAR（%）		TXB2（pg/mL）
组别	孕中期	孕晚期	孕中期	孕晚期
实验组	78.54±4.52	79.58±4.55	134.56±34.84	135.64±35.57
对照组	60.45±5.12	62.49±6.28	67.15±4.28	68.49±5.27
t值	21.518	12.070	15.601	10.228
P值	0.001	0.001	0.001	0.001

组别	TT（s）		PT（s）		APTT（s）		Fib（g/L）
组别	孕中期	孕晚期	孕中期	孕晚期	孕中期	孕晚期	孕中期	孕晚期
实验组	14.25±2.12	13.32±2.10	12.81±1.22	11.02±0.47	27.42±3.41	25.12±2.74	3.98±0.35	4.38±0.54
对照组	16.54±3.25	18.21±2.51	14.35±1.61	12.25±1.15	34.67±4.58	36.28±2.88	2.54±0.33	2.15±0.28
t值	4.794	12.139	6.192	8.043	10.315	22.808	24.319	16.428
P值	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001

组别	TT（s）		PT（s）		APTT（s）		Fib（g/L）
组别	孕中期	孕晚期	孕中期	孕晚期	孕中期	孕晚期	孕中期	孕晚期
实验组	14.25±2.12	13.32±2.10	12.81±1.22	11.02±0.47	27.42±3.41	25.12±2.74	3.98±0.35	4.38±0.54
对照组	16.54±3.25	18.21±2.51	14.35±1.61	12.25±1.15	34.67±4.58	36.28±2.88	2.54±0.33	2.15±0.28
t值	4.794	12.139	6.192	8.043	10.315	22.808	24.319	16.428
P值	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001

组别	t-PA（ng/mL）		vWF（%）
组别	孕中期	孕晚期	孕中期	孕晚期
实验组	1.92±0.30	1.64±0.21	142.56±15.98	150.54±16.27
对照组	4.35±1.47	4.21±1.42	88.56±11.34	100.24±10.26
t值	13.158	14.545	22.385	21.245
P值	0.001	0.001	0.001	0.001

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 7

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

组别	DD（mg/mL）		FDP（μg/mL）		TAT（μg/mL）		TM（IU/mL）
组别	孕中期	孕晚期	孕中期	孕晚期	孕中期	孕晚期	孕中期	孕晚期
实验组	0.45±0.34	1.25±0.25	3.26±1.25	8.95±2.51	4.25±1.26	5.26±1.33	7.25±1.22	9.89±5.25
对照组	0.10±0.05	0.12±0.10	1.22±0.45	4.58±2.15	2.59±0.67	2.60±0.54	4.21±0.58	5.31±0.61
t值	8.274	34.094	12.475	10.742	9.450	15.055	18.283	7.040
P值	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001

组别	DD（mg/mL）		FDP（μg/mL）		TAT（μg/mL）		TM（IU/mL）
组别	孕中期	孕晚期	孕中期	孕晚期	孕中期	孕晚期	孕中期	孕晚期
实验组	0.45±0.34	1.25±0.25	3.26±1.25	8.95±2.51	4.25±1.26	5.26±1.33	7.25±1.22	9.89±5.25
对照组	0.10±0.05	0.12±0.10	1.22±0.45	4.58±2.15	2.59±0.67	2.60±0.54	4.21±0.58	5.31±0.61
t值	8.274	34.094	12.475	10.742	9.450	15.055	18.283	7.040
P值	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001